Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Towa Expects To Grow By Over A Third With Pensa

Sees 5% Annual Increase On The Back Of New Launches

Executive Summary

Towa says it expects consolidating the Pensa business it acquired earlier this year to boost its sales by more than a third in its current financial year. Meanwhile, the Japanese firm has reported sales ahead by 5% in the year ended March 2020 on the back of new launches, as well as growth in profits despite local price cuts.

You may also be interested in...



Towa Hits Profit Target Three Months Early

Japan’s Towa has almost achieved its full-year operating profit goal in the first nine months of its financial year thanks to lower costs.

Towa Completes Deal For Pensa

Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.

AAM Urges US Senate To Back Domestic Production

While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”

Topics

Related Companies

UsernamePublicRestriction

Register

LL065251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel